Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC).
暂无分享，去创建一个
F. Saad | D. Penson | C. Sternberg | M. Hussain | K. Fizazi | E. Efstathiou | K. Madziarska | U. Ferreira | U. Giorgi | N. Shore | J. Sugg | Xun Lin | D. Cubero | J. Steinberg | K. Modelska | M. Kolinsky | F. Zohren | B. Noerby | P. Ivashchenko